Secondary Logo

Journal Logo

May/June 2022 - Volume 42 - Issue 3

  • Anthony J. Rothschild, MD
  • 0271-0749
  • 1533-712X
  • 6 issues / year
  • Psychiatry 69/155; Pharmacy and Pharmacology 133/270
  • 3.153

​​Photo -AJ Rothschild, MD in front of medical school.jpgWelcome to the May/June 2022 issue of the Journal of Clinical Psychopharmacology. There are many interesting and thought-provoking articles in this issue. I would like to highlight a few of them.  In this issue, there is an interesting commentary by Drs. Grabb and Potter entitled “Central Nervous System Trial Failures: Using the Fragile X Syndrome – mGluR5 Drug Target to Highlight the Complexities of Translating Preclinical Discoveries Into Human Trials" (pp. 234-237).  Drs. Grabb and Potter provide insight into why trials of central nervous system medications have been plagued with uninformative failures.  On pages 238-246, Dr. Mohamoud and colleagues from the Food and Drug Administration discuss acute hyperkinetic movement disorders that have been reported with the concomitant use of attention-deficit/hyperactivity disorder stimulants and antipsychotic medications in children and adolescents entitled “Acute Hyperkinetic Movement Disorders as a Multifactorial Pharmacodynamic Drug Interaction Between Methylphenidate and Risperidone in Children and Adolescents."  There is also an accompanying podcast by Dr. Mohamoud.   There are two interesting Brief Reports in this issue. The first, authored by Drs. Sonal and Srivastava, is entitled “Aripiprazole as First-Line Therapy for Late-Life Depression: A Case Note Review" (pp. 280-283).  The second, authored by Drs. Bonnet and Juckel, is entitled “COVID-19 Outcomes: Does the Use of Psychotropic Drugs Make a Difference? Accumulating Evidence of a Beneficial Effect of Antidepressants — A
Scoping Review" (pp. 284-292).  My Editorial in this issue is entitled “Should Antipsychotic Medications Be Prescribed to Patients With Nonpsychotic Depression?" (pp. 231-233).  In the Editorial, I discuss why, in my opinion, there should be a reconsideration of the risks and benefits of prescribing antipsychotic medications for nonpsychotic patients including patients with nonpsychotic depression, anxiety, or insomnia.  The Editorial is accompanied by a podcast.  And finally, on pages 336-337 is a salute to our invaluable reviewers who have contributed their time and expertise in evaluating the many articles submitted to the Journal of Clinical Psychopharmacology in 2021 and continuing into 2022. And as you will see, there are many other interesting Original Contributions and Letters to the Editor in the May/June issue!  ​

 Anthony J. Rothschild, MD

Editor-in-Chief

Current Issue Highlights